Home
Revascularisation for Ischaemic Ventricular Dysfunction
A multicentre prospective randomised open controlled trial.
Aim: To evaluate the efficacy and safety of percutaneous coronary intervention compared to optimal medical therapy alone for ischaemic left ventricular dysfunction.
Primary Endpoint: All-cause death or hospitalisation due to heart failure
Secondary Endpoints:
- Left Ventricular Ejection Fraction (LVEF) on echocardiography at 6 months and 1 year
- Quality of life score:
- Kansas City Cardiomyopathy Questionnaire (KCCQ) up to 2 years
- EuroQol EQ-5D-5L at 6 months and then yearly to the end of follow-up
- New York Heart Association Functional (NYHA) Functional Class up to 2 years
- Cardiovascular death over the entire duration of follow-up
- All-cause death over the entire duration of follow-up
- Hospitalisation for heart failure over the entire duration of follow-up
- Acute myocardial infarction (MI) over the entire duration of follow-up
- Appropriate implantable cardioverter defibrillator (ICD) therapy up to 2 years
- Unplanned further revascularisation over the entire duration of follow-up
- Canadian Cardiovascular Society (CCS) class up to 2 years
- NHS resource use
- Brain natriuretic peptide (BNP or NT-Pro BNP) level up to 2 years
- Major bleeding up to 2 years